Hasil Pencarian - Michael Sheaff

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    Immunoglobulin G4-related disease presenting with nephrotic syndrome due to minimal change disease: a case report

    Immunoglobulin G4-related disease presenting with nephrotic syndrome due to minimal change disease: a case report oleh Amy Needleman, Michael Sheaff, Ruth J. Pepper, Rhys D. R. Evans

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Transplant nephrectomy; pathological features of 124 consecutive cases in a single center study over 10 years

    Transplant nephrectomy; pathological features of 124 consecutive cases in a single center study over 10 years oleh Masaki Muramatsu, Yoji Hyodo, Abigail Lee, Atsushi Aikawa, Carmelo Puliatti, Magdi Yaqoob, Michael Sheaff

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

    BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. oleh Sara Busacca, Alex D Chacko, Astero Klabatsa, Kenneth Arthur, Michael Sheaff, Dario Barbone, Luciano Mutti, Vignesh K Gunasekharan, Julia J Gorski, Mohamed El-Tanani, V Courtney Broaddus, Giovanni Gaudino, Dean A Fennell

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Correction: BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma.

    Correction: BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. oleh Sara Busacca, Alex D. Chacko, Astero Klabatsa, Kenneth Arthur, Michael Sheaff, Dario Barbone, Luciano Mutti, Vignesh K. Gunasekharan, Julia J. Gorski, Mohamed El-Tanani, V. Courtney Broaddus, Giovanni Gaudino, Dean A. Fennell

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

    Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial oleh Dean A. Fennell, Catharine Porter, Jason Lester, Sarah Danson, Paul Taylor, Michael Sheaff, Robin M Rudd, Aarti Gaba, Sara Busacca, Lisette Nixon, Georgina Gardner, Liz Darlison, Charlotte Poile, Cathy Richards, Peter-Wells Jordan, Gareth Griffiths, Angela Casbard

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

    CAR T-cell immunotherapy of MET-expressing malignant mesothelioma oleh Thivyan Thayaparan, Roseanna M. Petrovic, Daniela Y. Achkova, Tomasz Zabinski, David M. Davies, Astero Klampatsa, Ana C. Parente-Pereira, Lynsey M. Whilding, Sjoukje JC van der Stegen, Natalie Woodman, Michael Sheaff, Jennifer R. Cochran, James F. Spicer, John Maher

    Diterbitkan 2017-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

    Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer oleh Peter W. Szlosarek, Akhila G. Wimalasingham, Melissa M. Phillips, Peter E. Hall, Pui Ying Chan, John Conibear, Louise Lim, Sukaina Rashid, Jeremy Steele, Paula Wells, Chiung‐Fang Shiu, Chih‐Ling Kuo, Xiaoxing Feng, Amanda Johnston, John Bomalaski, Stephen Ellis, Marianne Grantham, Michael Sheaff

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

    Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mech... oleh Peter W. Szlosarek, MD, PhD, Melissa M. Phillips, MD, PhD, Iuliia Pavlyk, PhD, Jeremy Steele, MD, Jonathan Shamash, MD, James Spicer, MD, PhD, Sanjeev Kumar, MD, Simon Pacey, MD, PhD, Xiaoxing Feng, PhD, Amanda Johnston, PhD, John Bomalaski, MD, Graeme Moir, MD, Kelvin Lau, MD, Stephen Ellis, MD, Michael Sheaff, MD

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: